- Home
- PGHL vs MGNX Comparison
PGHL vs MGNX Comparison
Compare PGHL & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGHL
- MGNX
- Stock Information
- Founded
- PGHL 2018
- MGNX 2000
- Country
- PGHL Hong Kong
- MGNX United States
- Employees
- PGHL N/A
- MGNX N/A
- Industry
- PGHL
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- PGHL
- MGNX Health Care
- Exchange
- PGHL NYSE
- MGNX Nasdaq
- Market Cap
- PGHL 189.6M
- MGNX 224.9M
- IPO Year
- PGHL 2024
- MGNX 2013
- Fundamental
- Price
- PGHL $13.70
- MGNX $4.30
- Analyst Decision
- PGHL
- MGNX Buy
- Analyst Count
- PGHL 0
- MGNX 11
- Target Price
- PGHL N/A
- MGNX $8.57
- AVG Volume (30 Days)
- PGHL 126.7K
- MGNX 712.7K
- Earning Date
- PGHL 11-15-2024
- MGNX 11-05-2024
- Dividend Yield
- PGHL N/A
- MGNX N/A
- EPS Growth
- PGHL N/A
- MGNX N/A
- EPS
- PGHL 0.05
- MGNX N/A
- Revenue
- PGHL $13,464,430.00
- MGNX $141,329,000.00
- Revenue This Year
- PGHL N/A
- MGNX $110.15
- Revenue Next Year
- PGHL N/A
- MGNX N/A
- P/E Ratio
- PGHL $287.21
- MGNX N/A
- Revenue Growth
- PGHL 20.83
- MGNX 16.68
- 52 Week Low
- PGHL $3.60
- MGNX $2.95
- 52 Week High
- PGHL $22.50
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- PGHL N/A
- MGNX 64.75
- Support Level
- PGHL N/A
- MGNX $3.61
- Resistance Level
- PGHL N/A
- MGNX $5.10
- Average True Range (ATR)
- PGHL 0.00
- MGNX 0.34
- MACD
- PGHL 0.00
- MGNX 0.07
- Stochastic Oscillator
- PGHL 0.00
- MGNX 62.94
About PGHL PRIMEGA GROUP HOLDINGS LIMITED
Primega Group Holdings Ltd is engaged in transportation services. It operate in the Hong Kong construction industry, mainly handling transportation of materials excavated from construction sites. Its services principally comprise of (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly includes ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from oil and rock transportation services.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).